MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 19(7): 916-929, 2018 07.
Article
in En
| MEDLINE
| ID: mdl-29908991
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Skin Neoplasms
/
Immunoconjugates
/
Immunotherapy
/
Melanoma
/
Antigens, Neoplasm
/
Neoplasm Proteins
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2018
Document type:
Article
Affiliation country:
Country of publication: